Related Experiment Videos

Low incidence of cardiac events in statin-administered patients in CAG study

Tomoaki Saeki1, Nagahiko Sakuma, Kiyoshi Hayakawa

  • 1Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.

Journal of Atherosclerosis and Thrombosis
|June 27, 2009
PubMed

Insights

Statins significantly reduced cardiac events in Japanese patients with coronary artery disease (CAD). This study shows statin therapy is effective for preventing cardiac events, including restenosis after percutaneous coronary intervention (PCI).

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary artery disease (CAD) is a significant health concern.
  • Statins are widely used to manage cholesterol levels.
  • The efficacy of statins in Japanese CAD patients requires specific investigation.

Purpose of the Study:

  • To evaluate the effectiveness of statins in preventing cardiac events in Japanese patients with coronary artery disease (CAD).
  • To assess the impact of statin therapy on lipid profiles and cardiac event incidence post-coronary angiography (CAG).

Main Methods:

  • A retrospective study of 148 Japanese CAD patients.
  • Patients were categorized into two groups: statin treatment (n=65) initiated within 2 weeks of CAG, and no statin treatment (n=83).
  • Cardiac events and lipid levels (Total Cholesterol - TC, Low-Density Lipoprotein Cholesterol - LDL-C) were monitored.

Main Results:

  • Statin administration significantly reduced TC and LDL-C (p<0.01).
  • The incidence of cardiac events was significantly lower in the statin group (8%) compared to the non-statin group (34%) (p<0.0003).
  • In patients with baseline TC < 200 mg/dL, statin use showed a trend towards preventing cardiac events (0% vs 25%, p<0.05).

Conclusions:

  • Statin therapy is effective in preventing cardiac events in Japanese CAD patients, regardless of baseline hypercholesterolemia.
  • Lowering LDL-C with statins is crucial for preventing recurrent cardiac events, including restenosis after percutaneous coronary intervention (PCI).
  • These findings support the use of statins for secondary prevention in Japanese CAD patients.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...